Ocular Therapeutix (OCUL) Net Cash Flow (2013 - 2026)

Ocular Therapeutix's Net Cash Flow history runs 14 years deep, the most recent figure standing at -$70.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 65.86% year-over-year to -$70.4 million; the TTM figure through Mar 2026 stood at $317.0 million (up 337.72% YoY), while the FY2025 annual figure was $345.0 million, up 75.87% from the prior year.
• Net Cash Flow was -$70.4 million for Q1 2026 at Ocular Therapeutix, down from $392.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $392.3 million in Q4 2025 to a low of -$70.4 million in Q1 2026.
• Historically, Net Cash Flow has averaged $29.6 million across 5 years, with a median of -$18.6 million in 2022.
• Biggest YoY gain for Net Cash Flow was 1333.48% in 2024; the steepest drop was 173.89% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$18.6 million in 2022, then soared by 557.14% to $85.3 million in 2023, then plunged by 141.19% to -$35.1 million in 2024, then surged by 1217.06% to $392.3 million in 2025, then slumped by 117.94% to -$70.4 million in 2026.
• The last three Net Cash Flow figures came in at -$70.4 million (Q1 2026), $392.3 million (Q4 2025), and -$46.4 million (Q3 2025), per Business Quant data.